NTT, NCNP’s brain digital twin tech aims to revamp disease prevention
NTT Corporation (NTT), a provider of IT infrastructure and services, and the National Center for Neurology and Psychiatry (NCNP) have partnered to develop “Brain Bio-Digital Twin” technology.
This collaboration aims to detect and prevent dementia, depression and other mental illnesses. By focusing on practical applications, NTT and NCNP strive to eliminate invasive and expensive testing for brain diseases.
NTT says the digital twin is timely as the prevalence of dementia and depression is rising. By 2025, it is estimated that over 6.5 million individuals aged 65 and above will have dementia in Japan alone. Additionally, the incidence of depression has more than doubled since the onset of the pandemic.
Furthermore, NTT claims its AI and ML technologies drive the Brain-Bio Digital Twin, and can help mitigate medical errors and accelerate the pace of drug trials.
NCNP is creating a library platform to effectively organize vast amounts of mental and nervous system disease data. Through the power of AI and ML, they intend to model disease states and develop an AI brain simulator to predict brain functions.
As part of the partnership, NCNP will provide image data and biosamples for analyzing cranial nerve diseases. They will also offer a medical interpretation of the relationship between AI/ML results and pathology, facilitating clinical implementation.
NTT leveraged the power of IoT and edge connectivity at the 2023 Tour de France and the Tour de France Femmes by integrating Zwift. The technology created a “connected stadium” via a digital twin that offered real-time information, digitizing all aspects of the sporting event.
Comments